Johnson & Johnson has completed its acquisition of Halda Therapeutics OpCo, Inc., strengthening the New Jersey-based healthcare company’s position in oncology research and development. The deal, valued at $3.05 billion in cash, brings a clinical-stage biotechnology platform into Johnson & Johnson’s Innovative Medicine division, adding new potential treatments for several types of solid tumors.
Halda Therapeutics is known for its proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC™)technology. The platform is designed to develop oral, targeted cancer therapies that selectively kill cancer cells while limiting damage to healthy tissue. According to Johnson & Johnson, the technology may help overcome resistance that often develops with existing cancer treatments.
A key asset included in the acquisition is HLD-0915, a once-daily oral therapy currently in clinical development for prostate cancer. Johnson & Johnson said the treatment builds on nearly two decades of research and innovation in prostate cancer, a disease area that remains a major focus within its oncology pipeline. In addition to HLD-0915, the acquisition brings earlier-stage candidates targeting breast cancer, lung cancer, and other solid tumors, all based on the RIPTAC™ platform.
Jennifer Taubert, executive vice president and worldwide chairman of Innovative Medicine at Johnson & Johnson, said the acquisition reflects the company’s long-term commitment to advancing cancer care. She noted that integrating Halda’s science and talent into Johnson & Johnson’s research organization aligns with its broader goal of delivering transformative medicines and improving patient outcomes.
John C. Reed, executive vice president of Innovative Medicine Research and Development, said the company will now focus on advancing Halda’s pipeline and expanding the use of RIPTAC™ technology. Reed emphasized that the platform could have applications beyond oncology, potentially opening the door to new targeted therapies in other disease areas over time.
From a financial perspective, Johnson & Johnson said the acquisition will be treated as a business combination. With the transaction closing in 2025, the company expects some near-term impact on earnings. Johnson & Johnson anticipates dilution in the fourth quarter of 2025 and throughout 2026, with total adjusted earnings per share dilution estimated at approximately $0.20, split evenly between the two years. The impact is largely attributed to non-recurring charges related to employee equity awards, financing, and integration costs associated with the acquisition.
The company said it plans to provide additional details on its full-year 2026 financial outlook during its fourth-quarter earnings call, scheduled for Wednesday, Jan. 21, 2026.
Headquartered in New Brunswick, Johnson & Johnson remains one of New Jersey’s largest employers and most prominent life sciences companies. The completion of the Halda Therapeutics acquisition further reinforces the state’s role as a major hub for pharmaceutical research, biotechnology innovation, and advanced cancer drug development.
